Lil­ly ax­es PhI­II tri­al of Verzenio in prostate can­cer

Eli Lil­ly culled a Phase III tri­al test­ing its can­cer drug Verzenio in pa­tients with cas­tra­tion-re­sis­tant prostate can­cer af­ter it failed to im­prove pro­gres­sion-free sur­vival in men with the dis­ease, the In­di­anapo­lis-based drug­mak­er said Mon­day.

Verzenio, when com­bined with Zyti­ga (abi­raterone), did not achieve the pri­ma­ry goal in the CY­CLONE-2 study, Lil­ly said as part of its quar­ter­ly earn­ings up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER